Clinically, HIF-2α inhibitors (e.g., belzutifan) have demonstrated efficacy across trials, with pooled data showing a 60% tumor response rate (95% CI: 52–68%; p < 0.001) and 70% progression-free survival (PFS) improvement (p < 0.01) (18, 26, 27). The gene discussed is EPAS1; the disease is neoplasm.